Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson

Core Insights - The U.S. liver cirrhosis treatment market is projected to reach approximately $15 billion by 2030, highlighting significant growth potential in this sector [3]. Company Overview - Can-Fite BioPharma Ltd. is a biotechnology company focused on developing proprietary small molecule drugs for oncological and inflammatory diseases, with its lead drug candidate Namodenoson showing promise in treating decompensated liver cirrhosis [1][5]. - Namodenoson is currently undergoing multiple clinical trials, including a pivotal Phase III trial for advanced liver cancer and a Phase IIb trial for Metabolic Dysfunction-associated Steatohepatitis (MASH) [4][5]. Clinical Development - A patient treated with Namodenoson under a compassionate use program has shown significant improvements, including the resolution of moderate ascites and a decrease in liver stiffness, indicating the drug's potential effectiveness [2][3]. - The positive response to Namodenoson is particularly noteworthy given the limited treatment options for decompensated liver disease, which often leads to liver transplantation [3]. Market Need - In 2017, approximately 10.6 million people globally were affected by decompensated cirrhosis, underscoring the urgent need for new therapeutic options as many patients face long wait times for liver transplants [3]. - The American Liver Foundation has indicated a critical shortage of donor organs, with some patients waiting over five years for a transplant, further emphasizing the market opportunity for effective treatments like Namodenoson [3].